Friday, July 10, 2026

Drug profile · INN

capromab pendetide

capromab pendetide (PROSTASCINT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — capromab pendetide
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

capromab pendetide (PROSTASCINT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN capromab pendetide
Brand PROSTASCINT
Mechanism Diagnostic agent
Route INTRAVENOUS
Formulation VIAL

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is capromab pendetide?

capromab pendetide (PROSTASCINT) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for capromab pendetide?

PROSTASCINT is a marketed brand name for capromab pendetide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of capromab pendetide?

capromab pendetide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.